



[SwissDock](#)




[SwissParam](#)



[SwissSidechain](#)



[SwissBioisostere](#)




[SwissTargetPrediction](#)




[SwissADME](#)



[Swiss Institute of Bioinformatics](#)

- [Terms of Use](#)
- [Contact](#)
- [Citing](#)
- [Help](#)
- [FAQ](#)
- [About](#)
- [Home](#)

For information: We have changed the look and feel of our tool. However, we have **NOT** changed the underlying technologies and parameters. Consequently, this updated Web tool provides exactly the same results as the previous version.



Enter a list of SMILES here:

`CC(=O)OC1=CC=CC=C1C(=O)O Aspirin`

Aspirin

Water Solubility

Log S (ESOL)

ESOL: Topological method implemented from Delaney JS. 2004 J. Chem. Inf. Model.

-1.85

Solubility 2.54e+00 mg/ml ; 1.41e-02 mol/l

Class

Solubility class: Log S scale

Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Very soluble

SMILES CC(=O)Oc1ccccc1C(=O)O

Physicochemical Properties

Formula C9H8O4

Molecular weight 180.16 g/mol

Num. heavy atoms 13

Num. arom. heavy atoms 6

Fraction Csp3 0.11

Num. rotatable bonds 3

Num. H-bond acceptors 4

Num. H-bond donors 1

Molar Refractivity 44.90

TPSA

Topological Polar Surface

Area: Calculated from 63.60 Å²
Ertl P. et al. 2000 J. Med. Chem.

Lipophilicity

Log P_{o/w} (iLOGP)

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

1.30

Log P_{o/w} (XLOGP3)

XLOGP3: Atomistic and knowledge-based method calculated by XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

1.19

Log P_{o/w} (WLOGP)

WLOGP: Atomistic method implemented from Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

1.31

Log P_{o/w} (MLOGP)

MLOGP: Topological method implemented from Moriguchi I. et al. 1992 Chem. Pharm. Bull. 1.51 Moriguchi I. et al. 1994 Chem. Pharm. Bull. Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

1.51

Log P_{o/w} (SILICOS-IT)

SILICOS-IT: Hybrid fragmental/topological method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, https://www.silicos-it.be

1.10

Log S (Ali)

Ali: Topological method implemented from Ali J. et al. 2012 J. Chem. Inf. Model.

-2.12

Solubility 1.36e+00 mg/ml ; 7.56e-03 mol/l

Class

Solubility class: Log S scale

Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble

Log S (SILICOS-IT)

SILICOS-IT: Fragmental method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, https://www.silicos-it.be

-1.85

Solubility 2.57e+00 mg/ml ; 1.43e-02 mol/l

Class

Solubility class: Log S scale

Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble

Pharmacokinetics

GI absorption

Gastrointestinal absorption: according to the white of the BOILED-Egg

High

BBB permeant

BBB permeation: according to the yolk of the BOILED-Egg

Yes

P-gp substrate

P-glycoprotein substrate: SVM model built on 1033 molecules (training set) and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

No

CYP1A2 inhibitor

Cytochrome P450 1A2

inhibitor: SVM model built on 9145 molecules (training set) and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

No

Consensus Log $P_{o/w}$

Consensus Log $P_{o/w}$: 1.28

Average of all five predictions

CYP2C19 inhibitor

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set) and tested on 3000 molecules (test set) No
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

CYP2C9 inhibitor

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set) and tested on 2075 molecules (test set) No
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

CYP2D6 inhibitor

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set) and tested on 1068 molecules (test set) No
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

CYP3A4 inhibitor

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set) and tested on 2579 molecules (test set) No
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

Log K_p (skin permeation)

Skin permeation: QSPR
model implemented from -6.55 cm/s
Potts RO and Guy RH. 1992
Pharm. Res.

Druglikeness

Lipinski

Lipinski (Pfizer) filter:
implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev. Yes; 0 violation
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

Ghose

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem. Yes
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

Veber

Veber (GSK) filter:
implemented from
Veber DF. et al. 2002 J. Med. Chem. Yes
Rotatable bonds ≤ 10
TPSA ≤ 140

Egan Yes

Egan (Pharmacia) filter:
implemented from
Egan WJ. et al. 2000 J. Med.

Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

Muegge

Muegge (Bayer) filter:

implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150 No; 1 violation: MW<200
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

Bioavailability Score

Abbott Bioavailability

Score: Probability of F > 10%
in rat 0.85
implemented from
Martin YC. 2005 J. Med. Chem.

Medicinal Chemistry

PAINS

Pan Assay Interference

Structures: implemented 0 alert
from
Baell JB. & Holloway GA.
2010 J. Med. Chem.

1 alert: phenol_ester

Brenk

Structural Alert:

implemented from
Brenk R. et al. 2008
ChemMedChem

Leadlikeness

Leadlikeness: implemented
from

Teague SJ. 1999 Angew. Chem. Int. Ed. No; 1 violation: MW<250
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

Synthetic accessibility

Synthetic accessibility

score: from 1 (very easy) to
10 (very difficult)
based on 1024 fragmental
contributions (FP2) 1.52
modulated by size and
complexity penalties,
trained on 12'782'590
molecules and tested on 40
external molecules ($r^2 = 0.94$)



This Web tool is operated by the [Molecular Modelling Group](#) of the [University of Lausanne](#) and the [SIB Swiss Institute of Bioinformatics](#) |
[Terms of use](#) | [SIB privacy policy](#)